ALK and cancer: High response rates (60–70%) are achieved with the EGFR TKIs in EGFR-mutated cancers (9) and ~60% of partial/complete responses with anaplastic lymphoma kinase (ALK) inhibitors (e.g., crizotinib) in patients with ALK translocations (17).